RWE Advancements Towards COVID-19 Therapeutics

11:05 AM - 11:50 AM (EDT), Tuesday, June 15, 2021
Search General Info
Search Education
Search Partnering Companies

The onset of the COVID-19 pandemic required rapid development and availability of potential COVID-19 treatments.  In the early weeks of the pandemic, the FDA looked to advanced analytical techniques and announced collaborations with public and private partners to collect and analyze a variety of real-world data sources.  This session will discuss application of RWE to advance emergency use authorization and/or approval of COVID-19 therapeutics.  The aim is to present a successful example bringing together multiple stakeholders from industry, FDA and healthcare technology. 

Senior Director, Science & Regulatory Affairs
Biotechnology Innovation Organization